NJ-LABVANTAGE
22.2.2024 13:31:32 CET | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, has made available its semantic search (AILANI), advanced analytics, and LIMS solutions in an integrated, digitally native ecosystem capable of seamlessly supporting R&D laboratory processes. This ecosystem will enable R&D labs to improve efficiency, productivity, decision-making, collaboration, and ultimately time-to-market while reducing operational cost. LabVantage will present its LIMS solutions and integrated ecosystem at Pittcon 2024 (Booth #2133), February 24-28, in San Diego, California.
Digitizing R&D laboratory processes with advanced technologies such as semantic search, analytics, and LIMS marks a significant leap towards efficiency and innovation in the scientific domain. Semantic search capabilities enable the contextualization and searchability of vast amounts of data and documents, utilizing a semantic core and knowledge graph. This technology not only streamlines information retrieval and drastically reduces repetition in experimental runs, but also enhances the decision-making process by providing more relevant and precise data insights. Some LabVantage customers have experienced a 30% reduction in repeated experiments by implementing LabVantage’s semantic search tool, AILANI.
Integrating AI and Business Intelligence into a unified analytics platform, in tandem with LIMS, accelerates analysis and reporting. LabVantage Analytics provides analysis of both structured and unstructured data from diverse sources, integrating data processing, storage, analysis, and visualization in one platform. Its user-friendly self-service features include customizable dashboards and immediate access to LIMS data reports.
“By incorporating advanced technologies like semantic search, AI, and analytics into our LIMS solutions, we're not only enhancing data precision and reducing experimental repetition but also driving significant improvements in collaboration and experiment design. Together, these tools will be instrumental in enabling customers to design better experiments while drastically reducing the total number of experimental runs,” said Alan Marcus, Chief Growth Officer at LabVantage Solutions. “Our goal is to hand back more time to customers for scientific exploration. In fact, we believe these digitally native solutions will expand our ability to serve clients in all supported industries throughout their entire product lifecycle. Your data can now be unified, housed, searched, and analyzed within a single platform from concept to market.”
The implementation of a LIMS automates and manages laboratory workflows, significantly boosting efficiency and consistency in experiment execution. By integrating with search and analytics tools, LabVantage LIMS ensures a seamless flow of information, further elevating laboratory operations, decision-making, and collaboration. Industry statistics underscore the transformative impact of such digitization and automation with laboratories reporting up to a 30-40% increase in productivity.1
LabVantage’s merger with Biomax Informatics has enhanced its analytics and LIMS solutions by integrating AILANI, an advanced semantic search tool. AILANI synergizes semantic modeling, ontologies, linguistics, and AI algorithms to revolutionize query-based research. This tool effectively connects various data sources—internal, external, and proprietary—empowering researchers to swiftly discover valuable insights and hidden patterns. It also simplifies and accelerates decision-making throughout the R&D process by offering easy access to relevant information and its context.
LabVantage Biomax was recognized in the Gartner® Hype Cycle™ for Life Science Discovery Research 2023 as a Sample Vendor for two categories: ‘Semantic Knowledge Graph Tools’ and ‘Analytics Platforms for Research Informatics’.2 Similarly, LabVantage was ranked as a top growth and innovation leader in 2023 by Frost & Sullivan in the firm’s first annual global life sciences LIMS report and radar, highlighting LabVantage's commitment and status as a pivotal player in transforming life science research and analytics.
For more information on LabVantage, its LIMS solutions, and digitally native R&D ecosystem, visit www.labvantage.com or email info@labvantage.com.
References:
- McKinsey & Company. Digitization, Automation, and Online Testing: The Future of Pharma Quality Control. McKinsey & Company Life Sciences.
-
Harwood, R. Gartner® Hype Cycle™ for Life Science Discovery Research, 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222841525/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom